Cencora (COR) 10-Q3 Aug 172017 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	AMERISOURCEBERGEN CORP
Entity Central Index Key	1,140,859
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		219,111,565
Trading Symbol	abc

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Current assets:
Cash and cash equivalents	$ 1,311,467	$ 2,741,832
Accounts receivable, less allowances for returns and doubtful accounts: $938,446 at June 30, 2017 and $905,345 at September 30, 2016	10,553,258	9,175,876
Merchandise inventories	11,669,529	10,723,920
Prepaid expenses and other	142,970	210,219
Total current assets	23,677,224	22,851,847
Property and equipment, at cost:
Land	40,292	40,290
Buildings and improvements	994,422	859,148
Machinery, equipment, and other	1,974,384	1,717,298
Total property and equipment	3,009,098	2,616,736
Less accumulated depreciation	(1,259,184)	(1,086,054)
Property and equipment, net	1,749,914	1,530,682
Goodwill	6,042,552	5,991,497
Other intangible assets	2,871,426	2,967,849
Other assets	312,894	295,626
TOTAL ASSETS	34,654,010	33,637,501
Current liabilities:
Accounts payable	24,804,544	23,926,320
Accrued expenses and other	942,413	743,839
Short-term debt	4,119	610,210
Total current liabilities	25,751,076	25,280,369
Long-term debt	3,429,074	3,576,493
Long-term financing obligation	352,719	275,991
Deferred income taxes	2,400,467	2,214,774
Other liabilities	167,160	160,470
Stockholders’ equity:
Common stock, $0.01 par value - authorized, issued, and outstanding: 600,000,000 shares, 280,371,836 shares, and 219,035,799 shares at June 30, 2017, respectively, and 600,000,000 shares, 277,753,762 shares, and 220,050,502 shares at September 30, 2016, respectively	2,804	2,778
Additional paid-in capital	4,498,536	4,333,001
Retained earnings	2,819,907	2,303,941
Accumulated other comprehensive loss	(112,458)	(114,308)
Treasury stock, at cost: 61,336,037 shares at June 30, 2017 and 57,703,260 shares at September 30, 2016	(4,655,275)	(4,396,008)
Total stockholders’ equity	2,553,514	2,129,404
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 34,654,010	$ 33,637,501

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Allowances for returns and doubtful accounts	$ 938,446	$ 905,345
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, authorized (shares)	600,000,000	600,000,000
Common stock, issued (shares)	280,371,836	277,753,762
Common stock, outstanding (shares)	219,035,799	220,050,502
Treasury stock (shares)	61,336,037	57,703,260

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended				9 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenue	$ 38,707,144			$ 36,881,680	$ 114,023,811	$ 109,289,083
Cost of goods sold	37,627,269			35,773,817	110,649,829	106,141,012
Gross profit	1,079,875			1,107,863	3,373,982	3,148,071
Operating expenses:
Distribution, selling, and administrative	525,463			516,438	1,567,853	1,560,981
Depreciation	59,478			54,000	173,083	157,861
Amortization	40,041			40,268	120,185	112,205
Warrants	0			(83,704)	0	(120,275)
Employee severance, litigation, and other	284,517			52,234	317,517	88,719
Pension settlement	0			0	0	47,607
Operating income	170,376			528,627	1,195,344	1,300,973
Other loss (income)	1,398			(2,158)	(3,958)	(3,224)
Interest expense, net	35,603			35,153	109,874	104,860
Income before income taxes	133,375			495,632	1,089,428	1,199,337
Income tax expense (benefit)	83,023			146,477	380,357	(82,907)
Net income	$ 50,352			$ 349,155	$ 709,071	$ 1,282,244
Earnings per share:
Basic (usd per share)	$ 0.23			$ 1.62	$ 3.25	$ 6.11
Diluted (usd per share)	$ 0.23			$ 1.55	$ 3.20	$ 5.68
Weighted average common shares outstanding:
Basic (shares)	218,676			215,688	218,336	209,898
Diluted (shares)	221,873			224,802	221,698	225,646
Cash dividends declared per share of common stock (usd per share)	$ 0.365	$ 0.365	$ 0.34	$ 0.34	$ 1.095	$ 1.02

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 50,352	$ 349,155	$ 709,071	$ 1,282,244
Other comprehensive income (loss)
Net change in foreign currency translation adjustments	10,841	(8,911)	1,829	(5,434)
Pension plan adjustment, net of tax of $19,054	0	0	0	31,538
Other	191	117	21	(749)
Total other comprehensive income (loss)	11,032	(8,794)	1,850	25,355
Total comprehensive income	$ 61,384	$ 340,361	$ 710,921	$ 1,307,599

CONSOLIDATED STATEMENTS OF COM6

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) $ in Thousands	9 Months Ended
	Jun. 30, 2016USD ($)
Statement of Comprehensive Income [Abstract]
Pension plan adjustments, tax	$ 19,054

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
OPERATING ACTIVITIES
Net income	$ 709,071	$ 1,282,244
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, including amounts charged to cost of goods sold	192,865	171,753
Amortization, including amounts charged to interest expense	127,395	116,961
Provision for doubtful accounts	8,651	11,310
Provision (benefit) for deferred income taxes	225,948	(220,739)
Warrants income	0	(120,275)
Share-based compensation	51,592	56,561
LIFO (credit) expense	(82,919)	274,305
Pension settlement	0	47,607
Other	(767)	(6,446)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:
Accounts receivable	(1,419,099)	(705,462)
Merchandise inventories	(829,903)	(949,887)
Prepaid expenses and other assets	23,844	35,270
Accounts payable	876,977	1,776,565
Accrued expenses, income taxes, and other liabilities	240,029	54,209
NET CASH PROVIDED BY OPERATING ACTIVITIES	123,684	1,823,976
INVESTING ACTIVITIES
Capital expenditures	(371,428)	(310,178)
Cost of acquired companies, net of cash acquired	(61,633)	(2,731,356)
Cost of equity investments	(8,300)	(19,034)
Proceeds from sales of investment securities available-for-sale	70,008	101,829
Purchases of investment securities available-for-sale	(48,635)	(41,136)
Other	13,422	(21,186)
NET CASH USED IN INVESTING ACTIVITIES	(406,566)	(3,021,061)
FINANCING ACTIVITIES
Term loan borrowings	0	1,000,000
Senior notes and term loans repayments	(750,000)	(600,000)
Borrowings under revolving and securitization credit facilities	6,784,159	8,788,432
Repayments under revolving and securitization credit facilities	(6,791,411)	(8,273,610)
Purchases of common stock	(229,928)	(1,023,149)
Exercises of warrants	0	1,168,891
Exercises of stock options, including excess tax benefits of $21,853 in fiscal 2016	94,325	73,356
Cash dividends on common stock	(240,168)	(215,070)
Tax withholdings related to restricted share vesting	(9,339)	(18,935)
Other	(5,121)	(5,070)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(1,147,483)	894,845
DECREASE IN CASH AND CASH EQUIVALENTS	(1,430,365)	(302,240)
Cash and cash equivalents at beginning of period	2,741,832	2,167,442
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 1,311,467	$ 1,865,202

CONSOLIDATED STATEMENTS OF CAS8

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	9 Months Ended
	Jun. 30, 2016USD ($)
Statement of Cash Flows [Abstract]
Excess tax benefits from exercises of stock options	$ 21,853

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of AmerisourceBergen Corporation and its wholly-owned subsidiaries (the "Company") as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of June 30, 2017 and the results of operations and cash flows for the interim periods ended June 30, 2017 and 2016 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 . The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation. Recently Adopted Accounting Pronouncements In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03"). ASU 2015-03 specifies that debt issuance costs related to a debt liability shall be reported on the balance sheet as a direct reduction from the face amount of the debt liability. In August 2015, the FASB issued ASU No. 2015-15, "Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" ("ASU 2015-15"). ASU 2015-15 specifies that debt issuance costs related to line-of-credit arrangements may be presented as an asset on the balance sheet and subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. As of October 1, 2016, the Company adopted ASU 2015-03 and ASU 2015-15 on a retrospective basis, which resulted in the reclassification of $18.7 million of debt issuance costs from Other Assets to Short-Term Debt of $0.9 million and to Long-Term Debt of $17.8 million on the Company's September 30, 2016 Consolidated Balance Sheet. The adoption had no impact on the Company’s results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, "Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee's shares than it may currently for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period. During the quarter ended December 31, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and established a deferred tax asset as of October 1, 2016 of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively. During the three and nine months ended June 30, 2017 , the Company recognized tax benefits of $10.0 million and $34.0 million , respectively, in Income Tax Expense on the Company's Consolidated Statement of Operations. The tax benefits recognized in the three and nine months ended June 30, 2017 are not necessarily indicative of amounts that may arise in future periods. Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification 605 — "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was originally scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. In July 2015, the Financial Accounting Standards Board deferred the effective date of ASU 2014-09 by one year. In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) — Principal versus Agent Considerations" ("ASU 2016-08"), which clarifies the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) — Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amends the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company must adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09. Entities are permitted to adopt the standards as early as the original public entity effective date of ASU 2014-09, and either full or modified retrospective application is required. The Company plans to adopt ASU 2014-09, ASU 2016-08, and ASU 2016-10 in the Company's fiscal year beginning October 1, 2019. The Company has not yet selected a transition method and is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of the above standards will have on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02"). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Entities are permitted to adopt the standard early, and a modified retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" ("ASU 2016-15"). ASU 2016-15 aims to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period, and a retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements. In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment" ("ASU 2017-04"). ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Entities are permitted to adopt the standard early for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company plans to early adopt this guidance during the fourth quarter of fiscal 2017 in conjunction with its annual goodwill impairment test. The Company does not expect any impact on its results of operations, cash flows, or financial position. As of June 30, 2017 , there were no other recently-issued accounting standards that may have a material impact on the Company’s financial position, results of operations, or cash flows upon their adoption.

Revision of Previously Issued F

Revision of Previously Issued Financial Statements	9 Months Ended
Revision of Previously Issued Financial Statements	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Revision of Previously Issued Financial Statements	Revision of Previously Issued Financial Statements In fiscal 2016, the Company engaged in a review of the accounting treatment of leases. As part of this review, the Company assessed its historical application of Accounting Standards Codification 840, "Leases," ("ASC 840") regarding lessee involvement in the construction of leased assets and identified corrections to be made in its accounting for these leases. In a number of its leases, the Company made payments for certain structural components included in the lessor's construction of the leased assets, which resulted in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, ASC 840 defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost on the balance sheet with a corresponding financing obligation. In these situations, the Company had not historically accounted for the total project costs of the lessor as owned assets. Additionally, upon completion of the lessor's project, the Company must perform a sale-leaseback analysis pursuant to ASC 840 to determine if it can derecognize these assets and the related financing obligations from its consolidated balance sheet. In a substantial number of its leases, due to many of the same factors that require it to account for the total project costs as owned assets during the construction period (for example, the Company funding a portion of the construction costs), it was deemed to have "continuing involvement," which precluded the Company from derecognizing these leased assets when construction was complete. In such cases, the leased assets and the related financing obligations remain on the consolidated balance sheet and are amortized over the life of the assets and the lease term, respectively. The Company revised the prior year's financial statements. The corrections reduced diluted earnings per share by $0.01 in both the three and nine months ended June 30, 2016. The Company no longer reports rent expense for the leased facilities that are owned for accounting purposes. Instead, rental payments under the leases are recognized as a reduction of the financing obligation and as interest expense. Additionally, depreciation expense is recorded as construction assets are depreciated over their useful lives. These corrections had no impact on the net decrease in cash and cash equivalents in the nine months ended June 30, 2016 . The following illustrates the impact the aforementioned adjustments had on the Company's previously issued financial statements: CONSOLIDATED STATEMENT OF OPERATIONS Three months ended June 30, 2016 (in thousands, except per share data) As Previously Reported Adjustments As Revised Revenue $ 36,881,680 $ — $ 36,881,680 Cost of goods sold 35,773,817 — 35,773,817 Gross profit 1,107,863 — 1,107,863 Operating expenses: Distribution, selling, and administrative 520,032 (3,594 ) 516,438 Depreciation 52,419 1,581 54,000 Amortization 40,268 — 40,268 Warrants (83,704 ) — (83,704 ) Employee severance, litigation, and other 52,234 — 52,234 Operating income 526,614 2,013 528,627 Other income (2,158 ) — (2,158 ) Interest expense, net 32,115 3,038 35,153 Income before income taxes 496,657 (1,025 ) 495,632 Income tax expense 146,854 (377 ) 146,477 Net income $ 349,803 $ (648 ) $ 349,155 Earnings per share: Basic $ 1.62 $ — $ 1.62 Diluted $ 1.56 $ (0.01 ) $ 1.55 Weighted average common shares outstanding: Basic 215,688 — 215,688 Diluted 224,802 — 224,802 CONSOLIDATED STATEMENT OF OPERATIONS Nine months ended June 30, 2016 (in thousands, except per share data) As Previously Reported Adjustments As Revised Revenue $ 109,289,083 $ — $ 109,289,083 Cost of goods sold 106,141,012 — 106,141,012 Gross profit 3,148,071 — 3,148,071 Operating expenses: Distribution, selling, and administrative 1,571,088 (10,107 ) 1,560,981 Depreciation 153,232 4,629 157,861 Amortization 112,205 — 112,205 Warrants (120,275 ) — (120,275 ) Employee severance, litigation, and other 88,719 — 88,719 Pension settlement 47,607 — 47,607 Operating income 1,295,495 5,478 1,300,973 Other income (3,224 ) — (3,224 ) Interest expense, net 96,107 8,753 104,860 Income before income taxes 1,202,612 (3,275 ) 1,199,337 Income tax benefit (81,703 ) (1,204 ) (82,907 ) Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Earnings per share: Basic $ 6.12 $ (0.01 ) $ 6.11 Diluted $ 5.69 $ (0.01 ) $ 5.68 Weighted average common shares outstanding: Basic 209,898 — 209,898 Diluted 225,646 — 225,646 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised Net income $ 349,803 $ (648 ) $ 349,155 Other comprehensive loss: Net change in foreign currency translation adjustments (8,911 ) — (8,911 ) Other 117 — 117 Total other comprehensive loss (8,794 ) — (8,794 ) Total comprehensive income $ 341,009 $ (648 ) $ 340,361 Nine months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Other comprehensive income: Net change in foreign currency translation adjustments (5,434 ) — (5,434 ) Pension plan adjustment, net of tax of $19,054 31,538 — 31,538 Other (749 ) — (749 ) Total other comprehensive income 25,355 — 25,355 Total comprehensive income $ 1,309,670 $ (2,071 ) $ 1,307,599 CONSOLIDATED STATEMENT OF CASH FLOWS Nine months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised OPERATING ACTIVITIES Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation, including amounts charged to cost of goods sold 167,124 4,629 171,753 Amortization, including amounts charged to interest expense 116,931 30 116,961 Provision for doubtful accounts 11,310 — 11,310 Benefit for deferred income taxes (219,535 ) (1,204 ) (220,739 ) Warrants income (120,275 ) — (120,275 ) Share-based compensation 56,561 — 56,561 LIFO expense 1 274,305 — 274,305 Pension settlement 47,607 — 47,607 Other (6,446 ) — (6,446 ) Changes in operating assets and liabilities, excluding the effects of acquisitions: Accounts receivable (705,462 ) — (705,462 ) Merchandise inventories 1 (949,887 ) — (949,887 ) Prepaid expenses and other assets 35,270 — 35,270 Accounts payable 1,776,565 — 1,776,565 Accrued expenses, income taxes, and other liabilities 53,575 634 54,209 NET CASH PROVIDED BY OPERATING ACTIVITIES 1,821,958 2,018 1,823,976 INVESTING ACTIVITIES Capital expenditures (310,178 ) — (310,178 ) Cost of acquired companies, net of cash acquired (2,731,356 ) — (2,731,356 ) Cost of equity investments (19,034 ) — (19,034 ) Proceeds from sales of investment securities available-for-sale 101,829 — 101,829 Purchases of investment securities available-for-sale (41,136 ) — (41,136 ) Other (21,186 ) — (21,186 ) NET CASH USED IN INVESTING ACTIVITIES (3,021,061 ) — (3,021,061 ) FINANCING ACTIVITIES Term loan borrowings 1,000,000 — 1,000,000 Term loan repayments (600,000 ) — (600,000 ) Borrowings under revolving and securitization credit facilities 8,788,432 — 8,788,432 Repayments under revolving and securitization credit facilities (8,273,610 ) — (8,273,610 ) Purchases of common stock (1,023,149 ) — (1,023,149 ) Exercises of warrants 1,168,891 — 1,168,891 Exercises of stock options, including excess tax benefits of $21,853 73,356 — 73,356 Cash dividends on common stock (215,070 ) — (215,070 ) Tax withholdings related to restricted share vesting (18,935 ) — (18,935 ) Other (3,052 ) (2,018 ) (5,070 ) NET CASH PROVIDED BY FINANCING ACTIVITIES 896,863 (2,018 ) 894,845 DECREASE IN CASH AND CASH EQUIVALENTS (302,240 ) — (302,240 ) Cash and cash equivalents at beginning of period 2,167,442 — 2,167,442 CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 1,865,202 $ — $ 1,865,202 1 Amounts as previously reported have been revised to report LIFO Expense separately from the change in Merchandise Inventories.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company files income tax returns in U.S. federal and state jurisdictions as well as various foreign jurisdictions. As of June 30, 2017 , the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company’s financial statements, of $100.8 million ( $72.0 million , net of federal benefit). If recognized, these tax benefits would reduce income tax expense and the effective tax rate. Included in this amount is $15.1 million of interest and penalties, which the Company records in income tax expense. During the nine months ended June 30, 2017 , unrecognized tax benefits increased by $12.6 million . Over the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $4.8 million . The Company's effective tax rates were 62.2% and 34.9% in the three and nine months ended June 30, 2017 , respectively. The Company's effective tax rates were 29.6% and (6.9)% in the three and nine months ended June 30, 2016 , respectively. The effective tax rates in the three and nine months ended June 30, 2017 were negatively impacted by non-deductible legal settlement charges (see Note 9 ), offset in part by certain discrete items, the growth of the Company's international businesses in Switzerland and Ireland that have significantly lower income tax rates, and the benefit from stock option exercises and restricted stock vesting. Prior to fiscal 2017, tax benefits resulting from share-based compensation were recorded as adjustments to Additional Paid-In Capital within Stockholders' Equity (see Note 1). The effective tax rate in the three months ended June 30, 2016 was favorably impacted primarily by the Company's international businesses that have lower income tax rates. The effective tax rate in the nine months ended June 30, 2016 primarily benefited from the receipt of an Internal Revenue Service private letter ruling that entitled the Company to an income tax deduction equal to the fair value of the Warrants on the dates of exercise.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
Goodwill and Other Intangible Assets	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the nine months ended June 30, 2017 : (in thousands) Pharmaceutical Distribution Services Other Total Goodwill at September 30, 2016 $ 4,264,485 $ 1,727,012 $ 5,991,497 Goodwill recognized in connection with acquisitions — 54,136 54,136 Goodwill disposed in connection with divestiture — (3,564 ) (3,564 ) Foreign currency translation — 483 483 Goodwill at June 30, 2017 $ 4,264,485 $ 1,778,067 $ 6,042,552 Following is a summary of other intangible assets: June 30, 2017 September 30, 2016 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Indefinite-lived trade names $ 685,016 $ — $ 685,016 $ 684,991 $ — $ 684,991 Finite-lived: Customer relationships 2,326,034 (374,591 ) 1,951,443 2,322,404 (273,638 ) 2,048,766 Trade names and other 326,397 (91,430 ) 234,967 307,234 (73,142 ) 234,092 Total other intangible assets $ 3,337,447 $ (466,021 ) $ 2,871,426 $ 3,314,629 $ (346,780 ) $ 2,967,849 Amortization expense for finite-lived intangible assets was $40.0 million and $40.3 million in the three months ended June 30, 2017 and 2016 , respectively. Amortization expense for finite-lived intangible assets was $120.2 million and $112.2 million in the nine months ended June 30, 2017 and 2016 , respectively. Amortization expense for finite-lived intangible assets is estimated to be $161.1 million in fiscal 2017 , $161.3 million in fiscal 2018 , $156.6 million in fiscal 2019 , $152.0 million in fiscal 2020 , $150.7 million in fiscal 2021 , and $1,525.3 million thereafter.

Debt

Debt	9 Months Ended
Debt	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	Debt Debt consisted of the following: (in thousands) June 30, September 30, Revolving credit note $ — $ — Receivables securitization facility due 2019 500,000 500,000 Term loans due in 2020 547,659 697,055 Multi-currency revolving credit facility due 2021 — — Overdraft facility due 2021 4,119 11,275 $600,000, 1.15% senior notes due 2017 — 598,935 $400,000, 4.875% senior notes due 2019 398,217 397,669 $500,000, 3.50% senior notes due 2021 497,748 497,361 $500,000, 3.40% senior notes due 2024 496,643 496,276 $500,000, 3.25% senior notes due 2025 494,779 494,266 $500,000, 4.25% senior notes due 2045 494,028 493,866 Total debt 3,433,193 4,186,703 Less current portion 4,119 610,210 Total, net of current portion $ 3,429,074 $ 3,576,493 In May 2017, the Company repaid the $600 million of 1.15% senior notes that became due. The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which expires in November 2021 , with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on the Company’s debt rating and ranges from 70 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable ( 91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee at June 30, 2017 ) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate , as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 5 basis points to 15 basis points , annually, of the total commitment ( 9 basis points at June 30, 2017 ). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of June 30, 2017 . The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company’s borrowing capacity as it is fully backed by the Company’s Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of June 30, 2017 . The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which expires in November 2019 . The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million , subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017 . The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million . The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI Animal Health ("MWI") business. In February 2015, the Company entered into a $1.0 billion variable-rate term loan ("February 2015 Term Loan"), which matures in 2020. Through June 30, 2017 , the Company elected to make principal payments, prior to the scheduled repayment dates, of $775 million on the February 2015 Term Loan, and as a result, the Company’s next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin, or LIBOR, plus a margin. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over LIBOR ( 100 basis points at June 30, 2017 ) and 0 basis points to 25 basis points over a base rate. The February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017 . In November 2015, the Company entered into a $1.0 billion variable-rate term loan ("November 2015 Term Loan"), which matures in 2020. In March 2016, the Company made a scheduled principal payment of $25 million . Additionally, through June 30, 2017 , the Company elected to make principal payments, prior to the scheduled repayment date, of $650 million on the November 2015 Term Loan, and as a result, the Company's next required principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or LIBOR, plus a margin. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over LIBOR ( 100 basis points at June 30, 2017 ) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017 .

Stockholders' Equity and Earnin

Stockholders' Equity and Earnings per Share	9 Months Ended
Stockholders' Equity and Earnings per Share	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity and Earnings per Share	Stockholders’ Equity and Earnings per Share In November 2016 , the Company’s board of directors increased the quarterly cash dividend by 7% from $0.340 per share to $0.365 per share. In May 2016, the Company's board of directors authorized a share repurchase program that, together with availability remaining under the previously approved August 2013 share repurchase program, permitted the Company to purchase up to $750 million of its outstanding shares of common stock, subject to market conditions. During the three months ended December 31, 2016, the Company purchased 2.1 million shares of its common stock (includes 0.5 million shares of common stock received as part of the settlement of the September 2016 accelerated share repurchase transaction) for a total of $118.8 million to complete its authorization under this program. In November 2016, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the nine months ended June 30, 2017 , the Company purchased 1.4 million shares of its common stock for a total of $111.1 million . As of June 30, 2017 , the Company had $888.9 million of availability remaining under the November 2016 share repurchase program. Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented, plus the dilutive effect of stock options, restricted stock, restricted stock units, and Warrants. Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Weighted average common shares outstanding - basic 218,676 215,688 218,336 209,898 Dilutive effect of stock options, restricted stock, and restricted stock units 3,197 3,042 3,362 3,440 Dilutive effect of Warrants — 6,072 — 12,308 Weighted average common shares outstanding - diluted 221,873 224,802 221,698 225,646 The potentially dilutive stock options, restricted stock, and restricted stock units that were antidilutive for the three and nine months ended June 30, 2017 were 3.7 million and 4.3 million , respectively. The potentially dilutive stock options, restricted stock, restricted stock units, and Warrants that were antidilutive for the three and nine months ended June 30, 2016 were 4.1 million and 2.6 million , respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Walgreens Boots Alliance, Inc. ("WBA") owns more than 10% of the Company’s outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement, pursuant to which the Company distributes branded and generic pharmaceutical products to WBA, and an agreement that provides the Company the ability to access generics and related pharmaceutical products through a global sourcing arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026. Revenue from the various agreements and arrangements with WBA was $11.2 billion and $33.4 billion in the three and nine months ended June 30, 2017 , respectively. Revenue from the various agreements and arrangements with WBA was $10.8 billion and $32.5 billion in the three and nine months ended June 30, 2016 , respectively. The Company’s receivable from WBA (after incentives owed to it) was $5.0 billion and $4.0 billion at June 30, 2017 and September 30, 2016 , respectively.

Employee Severance, Litigation,

Employee Severance, Litigation, and Other	9 Months Ended
Employee Severance, Litigation, and Other	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Employee Severance, Litigation, and Other	Employee Severance, Litigation, and Other The following table illustrates the charges by the Company relating to employee severance, litigation, and other for the three and nine months ended June 30, 2017 and 2016 : Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Litigation settlements $ 273,400 $ — $ 289,400 $ — Employee severance and other costs 9,584 34,554 21,767 40,247 Deal-related transaction costs 1,533 531 6,350 18,323 Transfer of surplus assets from a settled salaried defined benefit pension plan to a defined contribution 401(k) plan — 17,149 — 17,149 Customer contract dispute settlements — — — 13,000 Total employee severance, litigation, and other $ 284,517 $ 52,234 $ 317,517 $ 88,719 For the three months ended June 30, 2017 , the Company incurred $273.4 million of charges for litigation settlements (see Note 9 ), $9.6 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $1.5 million of deal-related transaction costs. For the nine months ended June 30, 2017 , the Company incurred $289.4 million of charges for litigation settlements, $21.8 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $6.4 million of deal-related transaction costs. For the three months ended June 30, 2016 , the Company incurred $34.6 million of employee severance and other costs, a $17.1 million charge related to the transfer of surplus assets from the Company's settled salaried defined benefit pension plan to its defined contribution 401(k) plan, and $0.5 million of deal-related transaction costs. For the nine months ended June 30, 2016 , the Company incurred $40.2 million of employee severance and other costs, $18.3 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from the Company's settled salaried defined benefit pension plan to its defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items). Employees receive their severance benefits over a period of time, generally not in excess of 12 months, or in the form of a lump-sum payment.

Legal Matters and Contingencies

Legal Matters and Contingencies	9 Months Ended
Legal Matters and Contingencies	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies	Legal Matters and Contingencies In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to the specific legal proceedings and claims described below, except as otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. Government Enforcement and Related Litigation Matters The Company is involved in government investigations and litigation arising from the marketing, promotion, sale, and dispensing of pharmaceutical products in the United States. Some of these investigations originate through what are known as qui tam complaints of the Federal False Claims Act. The qui tam provisions of the Federal Civil False Claims Act and various state and local civil False Claims Acts permit a private person, known as a "relator" or whistleblower, to file civil actions under these statutes on behalf of the federal, state, and local governments. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegations in the complaint and to determine whether or not to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise. Under the Federal False Claims Act, the government (or relators who pursue the claims without the participation of the government in the case) may seek to recover up to three times the amount of damages in addition to a civil penalty for each allegedly false claim submitted to the government for payment. Generally speaking, these cases take several years for the investigation to be completed and, ultimately, to be resolved (either through litigation or settlement) after the complaint is unsealed. In addition, some states have pursued investigations under state false claims statutes or consumer protection laws, either in conjunction with a government investigation or separately. There is often collateral litigation that arises from public disclosures of government investigations, including the filing of class action lawsuits by third party payors or by shareholders alleging violations of the securities laws. The Federal Food, Drug, and Cosmetic Act ("FDCA") contains provisions relating to the sale and distribution of pharmaceutical products that are alleged to be adulterated or misbranded. The FDCA includes strict-liability criminal offenses that can be pursued by the government for violations of the FDCA and which can result in the imposition of substantial fines and penalties against corporations and individuals. The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers. Subpoenas and Ongoing Investigations From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company generally responds to such subpoenas and requests in a cooperative manner. These responses often require time and effort and can result in considerable costs being incurred by the Company. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to substantial settlements. Since fiscal 2012, the Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") have been responding to subpoenas from the United States Attorney's Office for the Eastern District of New York ("USAO-EDNY") requesting production of documents and information relating to the pre-filled syringe program of ABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014. The Company has produced documents and witnesses, and has engaged in ongoing dialogue with the USAO-EDNY, since 2012. ABSG recently reached an agreement in principle with the USAO-EDNY which the Company understands will resolve the government’s criminal investigation in its entirety. The agreement in principle is subject to negotiation of final terms, approval by the parties and execution of definitive documents, and the approval of the Court. Under the terms of the agreement in principle, ABSG will pay $260.0 million and plead guilty to a strict liability misdemeanor offense under the FDCA in connection with the failure of Medical Initiatives, Inc. to duly register with the United States Food and Drug Administration, and the Company will enter into a Compliance Agreement with the United States Department of Justice. In connection with the agreement in principle, the Company recorded a litigation reserve of $260.0 million in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations for the three and nine months ended June 30, 2017. The USAO-EDNY has also indicated that it intends to pursue alleged civil claims under the False Claims Act. Discussions with the USAO-EDNY to resolve such claims are ongoing, however there are significant disagreements between the parties and it remains unclear whether a settlement can be reached at this time or whether the matter will proceed to litigation. Should the matter proceed to litigation, the Company intends to vigorously defend itself. Any settlement or other resolution of this civil matter could have an adverse effect on our business, results of operations, or cash flows. The Company is unable to reasonably estimate a range of loss, and no conclusion can be drawn at this time as to any likely outcome in this matter. In fiscal 2012, the Company's subsidiary AmerisourceBergen Drug Corporation ("ABDC") received a subpoena from the United States Attorney's Office for the District of New Jersey ("USAO-NJ") in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration ("DEA") in connection with the matter. Since fiscal 2012, ABDC has received and responded to a number of subpoenas from both the USAO-NJ and DEA requesting grand jury testimony and additional information related to electronically stored information, documents concerning specific customers' purchases of controlled substances, and DEA audits. In July 2017, the USAO-NJ and DEA served an administrative subpoena seeking records and requests relating to ABDC’s diversion control programs from 2013 to the present. The Company continues to engage in dialogue with the USAO-NJ, including discussions to attempt to reach a negotiated settlement. No conclusion can be drawn at this time as to any likely outcome in this matter. Since fiscal 2013, the Company or ABDC has received subpoenas from the United States Attorney's Office for the District of Kansas and the United States Attorney's Office for the Northern District of Ohio in connection with grand jury proceedings requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the USAO-NJ matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas have also requested documents concerning specific customers' purchases of controlled substances. The Company has responded to the subpoenas and requests for information. The Company’s subsidiary U.S. Bioservices Corporation ("US Bio") has reached an agreement in principle with the United States Attorney’s Office for the Southern District of New York ("USAO-SDNY") related to the previously disclosed matter involving the dispensing of one product and US Bio’s relationship with the manufacturer of that product. The Company understands that settlement pursuant to the agreement in principle will resolve the government’s investigation in its entirety. The agreement in principle is subject to negotiation of final terms, approval by the parties, and execution of definitive documents. Under the terms of the agreement in principle, this matter will be dismissed with prejudice pursuant to a settlement stipulation, upon entry by the Court, which will provide for the payment of $13.4 million and the express denial of the allegations and any wrongdoing. The Company recorded a litigation reserve of $13.4 million in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations for the three and nine months ended June 30, 2017. In January 2017, US Bio received a subpoena for information from the USAO-EDNY relating to US Bio’s activities in connection with billing for products and making returns of potential overpayments to government payers. The Company is engaged in discussions with the USAO-EDNY and will be producing documents in response to the subpoena. For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of ongoing investigations or their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity obligations and/or other civil and criminal penalties. State Proceedings In June 2012, the Attorney General of the State of West Virginia ("West Virginia AG") filed complaints, which were amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia AG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of $16.0 million and express denial of the allegations in the complaints and any wrongdoing. During the nine months ended June 30, 2017, the Company recognized the $16.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations. ABDC was sued in West Virginia state court by McDowell County, West Virginia on December 23, 2016, with an Amended Complaint filed on February 24, 2017, alleging, among other claims, negligence in the distribution of controlled substances, violation of the West Virginia Controlled Substances Act, and unjust enrichment. ABDC filed a notice of removal of this matter on January 26, 2017 and a motion to dismiss the Amended Complaint with prejudice on March 17, 2017. The county’s motion to remand was denied, so the case remains pending in federal court in West Virginia. ABDC was sued in state court by the City of Huntington, West Virginia on January 20, 2017, with an Amended Complaint filed on January 26, 2017 but not served, asserting similar claims to the McDowell County action, including for negligence, violation of the West Virginia Controlled Substances Act, and unjust enrichment. ABDC filed a notice of removal of this matter on February 23, 2017 and a motion to dismiss on March 2, 2017. Four additional cities, Williamson, Gilbert, Kermit and Welch, and the County Commission for Lincoln County have filed suit against ABDC asserting similar claims in state court. Each of those cases was removed to federal court and the deadlines for filing responsive pleadings, including motions to dismiss, are stayed until after briefing of the expected motions to remand. Additionally, seven County Commissions (Boone, Cabell, Fayette, Kanawha, Logan, Wayne and Wyoming) have filed suit in federal court, each asserting a single claim for public nuisance. ABDC has filed a motion to dismiss each of those federal complaints. The motions to dismiss the seven federal complaints were argued on June 20, 2017, and no decision has yet been issued on those motions. On April 24, 2017, a lawsuit was filed on behalf of the Cherokee Nation in the District Court for the Cherokee Nation against ABDC, other distributors, and pharmacies. This case alleges claims similar to those in the cases brought by certain counties and cities in West Virginia, including, among others, claims for violation of the Cherokee Nation Unfair and Deceptive Practices Act, nuisance, negligence/gross negligence and unjust enrichment. ABDC and its co-defendants filed a declaratory judgment action in the Northern District of Oklahoma seeking a judgment that the District Court for the Cherokee Nation lacks jurisdiction over the defendants and the claims. The defendants also filed a motion for preliminary injunction. The proceeding in the court of the Cherokee Nation is temporarily stayed pending the outcome of the preliminary injunction motion. The Cherokee Nation filed its response to the preliminary injunction motion on July 21, 2017. On June 5, 2017, the City of Dayton, Ohio filed a lawsuit against distributors, manufacturers of controlled substances, and key opinion leaders alleged to have promoted the use of certain controlled substances. The complaint asserts claims of violation of the Ohio Consumer Sales Practices statute, violation of the Ohio Deceptive Trade Practices statute, public nuisance under both statutory and common law, fraud and unjust enrichment against all defendants. A separate single count of negligence has also been alleged against distributor defendants. ABDC has not yet been served with the complaint from the City of Dayton. On July 7, 2017, the manufacturer defendants filed a notice of removal which alleges that the distributor defendants, including ABDC, are dispensable parties subject to severance, or were fraudulently misjoined. On June 29, 2017, the City of Lorain, Ohio filed a similar lawsuit containing the same allegations and claims as the Dayton lawsuit. ABDC has not yet filed responsive pleadings in either matter, but anticipates filing Motions to Dismiss at the appropriate time. On June 12, 2017, Nassau County, New York filed a lawsuit against distributors, manufacturers of controlled substances, and individuals. This lawsuit was filed by the same plaintiff’s counsel as the two Ohio cases and contains identical allegations and claims. ABDC has not filed a responsive pleading, but anticipates filing a motion to dismiss in advance of September 22, 2017, the date on which responsive pleadings are due. Other entities, including additional attorney general’s offices, counties and cities in multiple states, have indicated their intent to sue. ABDC intends to vigorously defend itself against the pending and any threatened lawsuits. The Company is not in a position to assess the likely outcome or its exposure, if any, with respect to these matters. Other Litigation On September 10, 2014, PharMerica Corp., Pharmacy Corporation of America and Chem Rx Pharmacy Services, LLC (collectively, "PMC"), customers of ABDC until March 3, 2015, filed a complaint in Jefferson Circuit Court in Louisville, Kentucky against ABDC. The original complaint alleged that ABDC failed to pay in excess of $8 million in rebates pursuant to a prime vendor agreement between PMC and ABDC under which ABDC distributed pharmaceuticals and other products to PMC. PMC subsequently amended its complaint three times. PMC’s current complaint alleges unpaid-rebate claims in excess of $33 million and additional breaches and damages for unspecified amounts, which amounts may exceed $100 million . ABDC answered all of the complaints, denied PMC’s allegations, and filed counterclaims alleging, among other things, that PMC failed to pay nearly $50 million in invoices related to pharmaceutical products it received from ABDC. On April 1, 2016, the Jefferson Circuit Court granted ABDC’s motion for partial summary judgment on one counterclaim and entered judgment in the amount of $48.6 million against PMC. On August 1, 2017, ABDC and PMC entered into an agreement in principle to resolve all claims in the litigation, including the pending judgment against PMC, for a one-time payment from PMC to ABDC of $3.1 million . As a result of this agreement in principle, the Company expects no impact to its consolidated results of operations. As part of the agreement in principle, the parties are requesting a stay of the judicial proceedings, which requires Court approval. The settlement of the litigation will not be effective unless and until a newly formed entity controlled by KKR & Co. L.P., with Walgreens Boots Alliance, Inc. as a minority investor, completes its acquisition of PMC, which is expected to be completed in early 2018.

Litigation Settlements

Litigation Settlements	9 Months Ended
Litigation Settlements	Jun. 30, 2017
Litigation Settlement [Abstract]
Litigation Settlements	Litigation Settlements Antitrust Settlements Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company has not been named a plaintiff in any of these class actions, but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actions have gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. The Company recognized no gains during the three months ended June 30, 2017 and recognized gains of $1.4 million during the nine months ended June 30, 2017 related to these class action lawsuits. During the three and nine months ended June 30, 2016 , the Company recognized gains of $121.0 million and $133.8 million , respectively, related to these class action lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s consolidated statements of operations.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The recorded amounts of the Company’s cash and cash equivalents, accounts receivable, and accounts payable at June 30, 2017 and September 30, 2016 approximate fair value based upon the relatively short-term nature of these financial instruments. The Company had no investments in money market accounts as of June 30, 2017 . Within cash and cash equivalents, the Company had $650.0 million of investments in money market accounts as of September 30, 2016 . The fair value of the money market accounts was determined based on unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs. The Company had $100.4 million of investment securities available-for-sale, $95.7 million of which were within cash and cash equivalents, at June 30, 2017 . The amortized cost of the investments was $100.4 million at June 30, 2017 . The Company had $39.1 million of investment securities available-for-sale, $13.0 million of which were within cash and cash equivalents, at September 30, 2016 . The amortized cost of the investments was $39.1 million at September 30, 2016 . The fair value of the investments was based on inputs other than quoted market prices, otherwise known as Level 2 inputs. The investments held as of June 30, 2017 consisted of fixed-income securities maturing in July 2017. The recorded amount of long-term debt (see Note 5) and the corresponding fair value as of June 30, 2017 were $3,429.1 million and $3,521.2 million , respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2016 were $3,576.5 million and $3,750.9 million , respectively. The fair value of long-term debt was determined based on Level 2 inputs, as defined above.

Business Segment Information

Business Segment Information	9 Months Ended
Business Segment Information	Jun. 30, 2017
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information The Company is organized based upon the products and services it provides to its customers. The Company’s operations are comprised of operating segments that are aggregated in the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation. The Pharmaceutical Distribution Services reportable segment consists of the ABDC and ABSG operating segments. Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health. In June 2017, the Company announced its intention to combine the ABDC and ABSG operating segments into a single operating segment. The Company expects this combination to be substantially completed by September 30, 2017. Additionally, upon completion of this reorganization, the Company's non-title third party logistics business (which is currently included within the Pharmaceutical Distribution Services reportable segment) will be combined with other operating segments that comprise Other, while ABCS's distribution business (currently included in Other) will be included in the Pharmaceutical Distribution Services reportable segment. The Company does not expect these changes to have a material impact to its historical reportable segment operating results. The following tables illustrate reportable segment information for the three and nine months ended June 30, 2017 and 2016 : Revenue Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Pharmaceutical Distribution Services $ 37,032,709 $ 35,373,725 $ 109,127,631 $ 104,734,137 Other 1,743,954 1,576,368 5,103,745 4,753,988 Intersegment eliminations (69,519 ) (68,413 ) (207,565 ) (199,042 ) Revenue $ 38,707,144 $ 36,881,680 $ 114,023,811 $ 109,289,083 Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution Services reportable segment. Segment Operating Income Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 (As Revised) (As Revised) Pharmaceutical Distribution Services $ 376,632 $ 412,731 $ 1,232,899 $ 1,294,150 Other 94,682 82,511 313,094 272,032 Intersegment eliminations (198 ) — $ (212 ) $ — Total segment operating income $ 471,116 $ 495,242 $ 1,545,781 $ 1,566,182 The following table reconciles total segment operating income to income before income taxes: Income Before Income Taxes Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 (As Revised) (As Revised) Total segment operating income $ 471,116 $ 495,242 $ 1,545,781 $ 1,566,182 Gain from antitrust litigation settlements — 120,960 1,395 133,758 LIFO credit (expense) 24,723 (80,364 ) 82,919 (274,305 ) Acquisition-related intangibles amortization (40,946 ) (38,681 ) (117,234 ) (108,611 ) Warrants income — 83,704 — 120,275 Employee severance, litigation, and other (284,517 ) (52,234 ) (317,517 ) (88,719 ) Pension settlement — — — (47,607 ) Operating income 170,376 528,627 1,195,344 1,300,973 Other loss (income) 1,398 (2,158 ) (3,958 ) (3,224 ) Interest expense, net 35,603 35,153 109,874 104,860 Income before income taxes $ 133,375 $ 495,632 $ 1,089,428 $ 1,199,337 Segment operating income is evaluated by the chief operating decision maker of the Company before gain from antitrust litigation settlements; LIFO credit (expense); acquisition-related intangibles amortization; Warrants income; employee severance, litigation, and other; pension settlement; other loss (income); and interest expense, net. All corporate office expenses are allocated to each operating segment.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of AmerisourceBergen Corporation and its wholly-owned subsidiaries (the "Company") as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of June 30, 2017 and the results of operations and cash flows for the interim periods ended June 30, 2017 and 2016 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 .
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03"). ASU 2015-03 specifies that debt issuance costs related to a debt liability shall be reported on the balance sheet as a direct reduction from the face amount of the debt liability. In August 2015, the FASB issued ASU No. 2015-15, "Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" ("ASU 2015-15"). ASU 2015-15 specifies that debt issuance costs related to line-of-credit arrangements may be presented as an asset on the balance sheet and subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. As of October 1, 2016, the Company adopted ASU 2015-03 and ASU 2015-15 on a retrospective basis, which resulted in the reclassification of $18.7 million of debt issuance costs from Other Assets to Short-Term Debt of $0.9 million and to Long-Term Debt of $17.8 million on the Company's September 30, 2016 Consolidated Balance Sheet. The adoption had no impact on the Company’s results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, "Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee's shares than it may currently for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period. During the quarter ended December 31, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and established a deferred tax asset as of October 1, 2016 of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively. During the three and nine months ended June 30, 2017 , the Company recognized tax benefits of $10.0 million and $34.0 million , respectively, in Income Tax Expense on the Company's Consolidated Statement of Operations. The tax benefits recognized in the three and nine months ended June 30, 2017 are not necessarily indicative of amounts that may arise in future periods. Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification 605 — "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was originally scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. In July 2015, the Financial Accounting Standards Board deferred the effective date of ASU 2014-09 by one year. In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) — Principal versus Agent Considerations" ("ASU 2016-08"), which clarifies the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) — Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amends the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company must adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09. Entities are permitted to adopt the standards as early as the original public entity effective date of ASU 2014-09, and either full or modified retrospective application is required. The Company plans to adopt ASU 2014-09, ASU 2016-08, and ASU 2016-10 in the Company's fiscal year beginning October 1, 2019. The Company has not yet selected a transition method and is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of the above standards will have on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02"). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Entities are permitted to adopt the standard early, and a modified retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" ("ASU 2016-15"). ASU 2016-15 aims to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period, and a retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements. In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment" ("ASU 2017-04"). ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Entities are permitted to adopt the standard early for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company plans to early adopt this guidance during the fourth quarter of fiscal 2017 in conjunction with its annual goodwill impairment test. The Company does not expect any impact on its results of operations, cash flows, or financial position. As of June 30, 2017 , there were no other recently-issued accounting standards that may have a material impact on the Company’s financial position, results of operations, or cash flows upon their adoption.

Revision of Previously Issued22

Revision of Previously Issued Financial Statements (Tables)	9 Months Ended
Revision of Previously Issued Financial Statements (Tables)	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Impact of adjustments on previously issued financial statements	The following illustrates the impact the aforementioned adjustments had on the Company's previously issued financial statements: CONSOLIDATED STATEMENT OF OPERATIONS Three months ended June 30, 2016 (in thousands, except per share data) As Previously Reported Adjustments As Revised Revenue $ 36,881,680 $ — $ 36,881,680 Cost of goods sold 35,773,817 — 35,773,817 Gross profit 1,107,863 — 1,107,863 Operating expenses: Distribution, selling, and administrative 520,032 (3,594 ) 516,438 Depreciation 52,419 1,581 54,000 Amortization 40,268 — 40,268 Warrants (83,704 ) — (83,704 ) Employee severance, litigation, and other 52,234 — 52,234 Operating income 526,614 2,013 528,627 Other income (2,158 ) — (2,158 ) Interest expense, net 32,115 3,038 35,153 Income before income taxes 496,657 (1,025 ) 495,632 Income tax expense 146,854 (377 ) 146,477 Net income $ 349,803 $ (648 ) $ 349,155 Earnings per share: Basic $ 1.62 $ — $ 1.62 Diluted $ 1.56 $ (0.01 ) $ 1.55 Weighted average common shares outstanding: Basic 215,688 — 215,688 Diluted 224,802 — 224,802 CONSOLIDATED STATEMENT OF OPERATIONS Nine months ended June 30, 2016 (in thousands, except per share data) As Previously Reported Adjustments As Revised Revenue $ 109,289,083 $ — $ 109,289,083 Cost of goods sold 106,141,012 — 106,141,012 Gross profit 3,148,071 — 3,148,071 Operating expenses: Distribution, selling, and administrative 1,571,088 (10,107 ) 1,560,981 Depreciation 153,232 4,629 157,861 Amortization 112,205 — 112,205 Warrants (120,275 ) — (120,275 ) Employee severance, litigation, and other 88,719 — 88,719 Pension settlement 47,607 — 47,607 Operating income 1,295,495 5,478 1,300,973 Other income (3,224 ) — (3,224 ) Interest expense, net 96,107 8,753 104,860 Income before income taxes 1,202,612 (3,275 ) 1,199,337 Income tax benefit (81,703 ) (1,204 ) (82,907 ) Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Earnings per share: Basic $ 6.12 $ (0.01 ) $ 6.11 Diluted $ 5.69 $ (0.01 ) $ 5.68 Weighted average common shares outstanding: Basic 209,898 — 209,898 Diluted 225,646 — 225,646 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised Net income $ 349,803 $ (648 ) $ 349,155 Other comprehensive loss: Net change in foreign currency translation adjustments (8,911 ) — (8,911 ) Other 117 — 117 Total other comprehensive loss (8,794 ) — (8,794 ) Total comprehensive income $ 341,009 $ (648 ) $ 340,361 Nine months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Other comprehensive income: Net change in foreign currency translation adjustments (5,434 ) — (5,434 ) Pension plan adjustment, net of tax of $19,054 31,538 — 31,538 Other (749 ) — (749 ) Total other comprehensive income 25,355 — 25,355 Total comprehensive income $ 1,309,670 $ (2,071 ) $ 1,307,599 CONSOLIDATED STATEMENT OF CASH FLOWS Nine months ended June 30, 2016 (in thousands) As Previously Reported Adjustments As Revised OPERATING ACTIVITIES Net income $ 1,284,315 $ (2,071 ) $ 1,282,244 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation, including amounts charged to cost of goods sold 167,124 4,629 171,753 Amortization, including amounts charged to interest expense 116,931 30 116,961 Provision for doubtful accounts 11,310 — 11,310 Benefit for deferred income taxes (219,535 ) (1,204 ) (220,739 ) Warrants income (120,275 ) — (120,275 ) Share-based compensation 56,561 — 56,561 LIFO expense 1 274,305 — 274,305 Pension settlement 47,607 — 47,607 Other (6,446 ) — (6,446 ) Changes in operating assets and liabilities, excluding the effects of acquisitions: Accounts receivable (705,462 ) — (705,462 ) Merchandise inventories 1 (949,887 ) — (949,887 ) Prepaid expenses and other assets 35,270 — 35,270 Accounts payable 1,776,565 — 1,776,565 Accrued expenses, income taxes, and other liabilities 53,575 634 54,209 NET CASH PROVIDED BY OPERATING ACTIVITIES 1,821,958 2,018 1,823,976 INVESTING ACTIVITIES Capital expenditures (310,178 ) — (310,178 ) Cost of acquired companies, net of cash acquired (2,731,356 ) — (2,731,356 ) Cost of equity investments (19,034 ) — (19,034 ) Proceeds from sales of investment securities available-for-sale 101,829 — 101,829 Purchases of investment securities available-for-sale (41,136 ) — (41,136 ) Other (21,186 ) — (21,186 ) NET CASH USED IN INVESTING ACTIVITIES (3,021,061 ) — (3,021,061 ) FINANCING ACTIVITIES Term loan borrowings 1,000,000 — 1,000,000 Term loan repayments (600,000 ) — (600,000 ) Borrowings under revolving and securitization credit facilities 8,788,432 — 8,788,432 Repayments under revolving and securitization credit facilities (8,273,610 ) — (8,273,610 ) Purchases of common stock (1,023,149 ) — (1,023,149 ) Exercises of warrants 1,168,891 — 1,168,891 Exercises of stock options, including excess tax benefits of $21,853 73,356 — 73,356 Cash dividends on common stock (215,070 ) — (215,070 ) Tax withholdings related to restricted share vesting (18,935 ) — (18,935 ) Other (3,052 ) (2,018 ) (5,070 ) NET CASH PROVIDED BY FINANCING ACTIVITIES 896,863 (2,018 ) 894,845 DECREASE IN CASH AND CASH EQUIVALENTS (302,240 ) — (302,240 ) Cash and cash equivalents at beginning of period 2,167,442 — 2,167,442 CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 1,865,202 $ — $ 1,865,202 1 Amounts as previously reported have been revised to report LIFO Expense separately from the change in Merchandise Inventories.

Goodwill and Other Intangible23

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
Goodwill and Other Intangible Assets (Tables)	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying value of goodwill by reportable segment	Following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the nine months ended June 30, 2017 : (in thousands) Pharmaceutical Distribution Services Other Total Goodwill at September 30, 2016 $ 4,264,485 $ 1,727,012 $ 5,991,497 Goodwill recognized in connection with acquisitions — 54,136 54,136 Goodwill disposed in connection with divestiture — (3,564 ) (3,564 ) Foreign currency translation — 483 483 Goodwill at June 30, 2017 $ 4,264,485 $ 1,778,067 $ 6,042,552
Schedule of indefinite-lived intangible assets	Following is a summary of other intangible assets: June 30, 2017 September 30, 2016 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Indefinite-lived trade names $ 685,016 $ — $ 685,016 $ 684,991 $ — $ 684,991 Finite-lived: Customer relationships 2,326,034 (374,591 ) 1,951,443 2,322,404 (273,638 ) 2,048,766 Trade names and other 326,397 (91,430 ) 234,967 307,234 (73,142 ) 234,092 Total other intangible assets $ 3,337,447 $ (466,021 ) $ 2,871,426 $ 3,314,629 $ (346,780 ) $ 2,967,849
Schedule of finite-lived intangible assets	Following is a summary of other intangible assets: June 30, 2017 September 30, 2016 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Indefinite-lived trade names $ 685,016 $ — $ 685,016 $ 684,991 $ — $ 684,991 Finite-lived: Customer relationships 2,326,034 (374,591 ) 1,951,443 2,322,404 (273,638 ) 2,048,766 Trade names and other 326,397 (91,430 ) 234,967 307,234 (73,142 ) 234,092 Total other intangible assets $ 3,337,447 $ (466,021 ) $ 2,871,426 $ 3,314,629 $ (346,780 ) $ 2,967,849

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of debt instruments	Debt consisted of the following: (in thousands) June 30, September 30, Revolving credit note $ — $ — Receivables securitization facility due 2019 500,000 500,000 Term loans due in 2020 547,659 697,055 Multi-currency revolving credit facility due 2021 — — Overdraft facility due 2021 4,119 11,275 $600,000, 1.15% senior notes due 2017 — 598,935 $400,000, 4.875% senior notes due 2019 398,217 397,669 $500,000, 3.50% senior notes due 2021 497,748 497,361 $500,000, 3.40% senior notes due 2024 496,643 496,276 $500,000, 3.25% senior notes due 2025 494,779 494,266 $500,000, 4.25% senior notes due 2045 494,028 493,866 Total debt 3,433,193 4,186,703 Less current portion 4,119 610,210 Total, net of current portion $ 3,429,074 $ 3,576,493

Stockholders' Equity and Earn25

Stockholders' Equity and Earnings per Share (Tables)	9 Months Ended
Stockholders' Equity and Earnings per Share (Tables)	Jun. 30, 2017
Equity [Abstract]
Schedule of weighted average number of common shares outstanding	Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Weighted average common shares outstanding - basic 218,676 215,688 218,336 209,898 Dilutive effect of stock options, restricted stock, and restricted stock units 3,197 3,042 3,362 3,440 Dilutive effect of Warrants — 6,072 — 12,308 Weighted average common shares outstanding - diluted 221,873 224,802 221,698 225,646

Employee Severance, Litigatio26

Employee Severance, Litigation, and Other (Tables)	9 Months Ended
Employee Severance, Litigation, and Other (Tables)	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Employee severance, litigation, and other charge	The following table illustrates the charges by the Company relating to employee severance, litigation, and other for the three and nine months ended June 30, 2017 and 2016 : Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Litigation settlements $ 273,400 $ — $ 289,400 $ — Employee severance and other costs 9,584 34,554 21,767 40,247 Deal-related transaction costs 1,533 531 6,350 18,323 Transfer of surplus assets from a settled salaried defined benefit pension plan to a defined contribution 401(k) plan — 17,149 — 17,149 Customer contract dispute settlements — — — 13,000 Total employee severance, litigation, and other $ 284,517 $ 52,234 $ 317,517 $ 88,719

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
Business Segment Information (Tables)	Jun. 30, 2017
Segment Reporting [Abstract]
Segment revenue	The following tables illustrate reportable segment information for the three and nine months ended June 30, 2017 and 2016 : Revenue Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 Pharmaceutical Distribution Services $ 37,032,709 $ 35,373,725 $ 109,127,631 $ 104,734,137 Other 1,743,954 1,576,368 5,103,745 4,753,988 Intersegment eliminations (69,519 ) (68,413 ) (207,565 ) (199,042 ) Revenue $ 38,707,144 $ 36,881,680 $ 114,023,811 $ 109,289,083
Segment operating income	Segment Operating Income Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 (As Revised) (As Revised) Pharmaceutical Distribution Services $ 376,632 $ 412,731 $ 1,232,899 $ 1,294,150 Other 94,682 82,511 313,094 272,032 Intersegment eliminations (198 ) — $ (212 ) $ — Total segment operating income $ 471,116 $ 495,242 $ 1,545,781 $ 1,566,182
Reconciliation of total segment operating income to income (loss) from operations before income taxes	The following table reconciles total segment operating income to income before income taxes: Income Before Income Taxes Three months ended Nine months ended (in thousands) 2017 2016 2017 2016 (As Revised) (As Revised) Total segment operating income $ 471,116 $ 495,242 $ 1,545,781 $ 1,566,182 Gain from antitrust litigation settlements — 120,960 1,395 133,758 LIFO credit (expense) 24,723 (80,364 ) 82,919 (274,305 ) Acquisition-related intangibles amortization (40,946 ) (38,681 ) (117,234 ) (108,611 ) Warrants income — 83,704 — 120,275 Employee severance, litigation, and other (284,517 ) (52,234 ) (317,517 ) (88,719 ) Pension settlement — — — (47,607 ) Operating income 170,376 528,627 1,195,344 1,300,973 Other loss (income) 1,398 (2,158 ) (3,958 ) (3,224 ) Interest expense, net 35,603 35,153 109,874 104,860 Income before income taxes $ 133,375 $ 495,632 $ 1,089,428 $ 1,199,337

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Oct. 01, 2016	Sep. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Excess tax benefits, share-based compensation	$ 10	$ 34
Accounting Standards Update 2015-03 \| Other assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs				$ (18.7)
Accounting Standards Update 2015-03 \| Short-term debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs				0.9
Accounting Standards Update 2015-03 \| Long-term debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs				$ 17.8
Accounting Standards Update 2016-09 \| New Accounting Pronouncement, Early Adoption, Effect
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred tax asset, share-based compensation			$ 47.1
Accounting Standards Update 2016-09 \| New Accounting Pronouncement, Early Adoption, Effect \| Retained earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment, share-based compensation			$ 47.1

Revision of Previously Issued29

Revision of Previously Issued Financial Statements - Additional Information (Details) - $ / shares	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Diluted earnings per share (usd per share)	$ 0.23	$ 1.55	$ 3.20	$ 5.68
Error Correction, Lease Accounting \| Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Diluted earnings per share (usd per share)		$ (0.01)		$ (0.01)

Revision of Previously Issued30

Revision of Previously Issued Financial Statements - Consolidated Statements of Operations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 38,707,144	$ 36,881,680	$ 114,023,811	$ 109,289,083
Cost of goods sold	37,627,269	35,773,817	110,649,829	106,141,012
Gross profit	1,079,875	1,107,863	3,373,982	3,148,071
Operating expenses:
Distribution, selling, and administrative	525,463	516,438	1,567,853	1,560,981
Depreciation	59,478	54,000	173,083	157,861
Amortization	40,041	40,268	120,185	112,205
Warrants	0	(83,704)	0	(120,275)
Employee severance, litigation, and other	284,517	52,234	317,517	88,719
Pension settlement	0	0	0	47,607
Operating income	170,376	528,627	1,195,344	1,300,973
Other loss (income)	1,398	(2,158)	(3,958)	(3,224)
Interest expense, net	35,603	35,153	109,874	104,860
Income before income taxes	133,375	495,632	1,089,428	1,199,337
Income tax expense (benefit)	83,023	146,477	380,357	(82,907)
Net income	$ 50,352	$ 349,155	$ 709,071	$ 1,282,244
Earnings per share:
Basic (usd per share)	$ 0.23	$ 1.62	$ 3.25	$ 6.11
Diluted (usd per share)	$ 0.23	$ 1.55	$ 3.20	$ 5.68
Weighted average common shares outstanding:
Basic (shares)	218,676	215,688	218,336	209,898
Diluted (shares)	221,873	224,802	221,698	225,646
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue		$ 36,881,680		$ 109,289,083
Cost of goods sold		35,773,817		106,141,012
Gross profit		1,107,863		3,148,071
Operating expenses:
Distribution, selling, and administrative		520,032		1,571,088
Depreciation		52,419		153,232
Amortization		40,268		112,205
Warrants		(83,704)		(120,275)
Employee severance, litigation, and other		52,234		88,719
Pension settlement				47,607
Operating income		526,614		1,295,495
Other loss (income)		(2,158)		(3,224)
Interest expense, net		32,115		96,107
Income before income taxes		496,657		1,202,612
Income tax expense (benefit)		146,854		(81,703)
Net income		$ 349,803		$ 1,284,315
Earnings per share:
Basic (usd per share)		$ 1.62		$ 6.12
Diluted (usd per share)		$ 1.56		$ 5.69
Weighted average common shares outstanding:
Basic (shares)		215,688		209,898
Diluted (shares)		224,802		225,646
Adjustments \| Error Correction, Lease Accounting
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue		$ 0		$ 0
Cost of goods sold		0		0
Gross profit		0		0
Operating expenses:
Distribution, selling, and administrative		(3,594)		(10,107)
Depreciation		1,581		4,629
Amortization		0		0
Warrants		0		0
Employee severance, litigation, and other		0		0
Pension settlement				0
Operating income		2,013		5,478
Other loss (income)		0		0
Interest expense, net		3,038		8,753
Income before income taxes		(1,025)		(3,275)
Income tax expense (benefit)		(377)		(1,204)
Net income		$ (648)		$ (2,071)
Earnings per share:
Basic (usd per share)		$ 0		$ (0.01)
Diluted (usd per share)		$ (0.01)		$ (0.01)
Weighted average common shares outstanding:
Basic (shares)		0		0
Diluted (shares)		0		0

Revision of Previously Issued31

Revision of Previously Issued Financial Statements - Consolidated Statements of Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ 50,352	$ 349,155	$ 709,071	$ 1,282,244
Other comprehensive income (loss)
Net change in foreign currency translation adjustments	10,841	(8,911)	1,829	(5,434)
Pension plan adjustment, net of tax of $19,054	0	0	0	31,538
Other	191	117	21	(749)
Total other comprehensive income (loss)	11,032	(8,794)	1,850	25,355
Total comprehensive income	$ 61,384	340,361	$ 710,921	1,307,599
Other comprehensive income (loss), parenthetical disclosures:
Pension plan adjustments, tax				19,054
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		349,803		1,284,315
Other comprehensive income (loss)
Net change in foreign currency translation adjustments		(8,911)		(5,434)
Pension plan adjustment, net of tax of $19,054				31,538
Other		117		(749)
Total other comprehensive income (loss)		(8,794)		25,355
Total comprehensive income		341,009		1,309,670
Other comprehensive income (loss), parenthetical disclosures:
Pension plan adjustments, tax				19,054
Adjustments \| Error Correction, Lease Accounting
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		(648)		(2,071)
Other comprehensive income (loss)
Net change in foreign currency translation adjustments		0		0
Pension plan adjustment, net of tax of $19,054				0
Other		0		0
Total other comprehensive income (loss)		0		0
Total comprehensive income		$ (648)		(2,071)
Other comprehensive income (loss), parenthetical disclosures:
Pension plan adjustments, tax				$ 0

Revision of Previously Issued32

Revision of Previously Issued Financial Statements - Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
OPERATING ACTIVITIES
Net income	$ 50,352	$ 349,155	$ 709,071	$ 1,282,244
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, including amounts charged to cost of goods sold			192,865	171,753
Amortization, including amounts charged to interest expense			127,395	116,961
Provision for doubtful accounts			8,651	11,310
Provision (benefit) for deferred income taxes			225,948	(220,739)
Warrants income			0	(120,275)
Share-based compensation			51,592	56,561
LIFO (credit) expense			(82,919)	274,305
Pension settlement	0	0	0	47,607
Other			(767)	(6,446)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:
Accounts receivable			(1,419,099)	(705,462)
Merchandise inventories			(829,903)	(949,887)
Prepaid expenses and other assets			23,844	35,270
Accounts payable			876,977	1,776,565
Accrued expenses, income taxes, and other liabilities			240,029	54,209
NET CASH PROVIDED BY OPERATING ACTIVITIES			123,684	1,823,976
INVESTING ACTIVITIES
Capital expenditures			(371,428)	(310,178)
Cost of acquired companies, net of cash acquired			(61,633)	(2,731,356)
Cost of equity investments			(8,300)	(19,034)
Proceeds from sales of investment securities available-for-sale			70,008	101,829
Purchases of investment securities available-for-sale			(48,635)	(41,136)
Other			13,422	(21,186)
NET CASH USED IN INVESTING ACTIVITIES			(406,566)	(3,021,061)
FINANCING ACTIVITIES
Term loan borrowings			0	1,000,000
Senior notes and term loans repayments			(750,000)	(600,000)
Borrowings under revolving and securitization credit facilities			6,784,159	8,788,432
Repayments under revolving and securitization credit facilities			(6,791,411)	(8,273,610)
Purchases of common stock			(229,928)	(1,023,149)
Exercises of warrants			0	1,168,891
Exercises of stock options, including excess tax benefits of $21,853 in fiscal 2016			94,325	73,356
Cash dividends on common stock			(240,168)	(215,070)
Tax withholdings related to restricted share vesting			(9,339)	(18,935)
Other			(5,121)	(5,070)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES			(1,147,483)	894,845
DECREASE IN CASH AND CASH EQUIVALENTS			(1,430,365)	(302,240)
Cash and cash equivalents at beginning of period			2,741,832	2,167,442
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 1,311,467	1,865,202	$ 1,311,467	1,865,202
Cash flow, parenthetical information:
Excess tax benefits from exercises of stock options				21,853
As Previously Reported
OPERATING ACTIVITIES
Net income		349,803		1,284,315
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, including amounts charged to cost of goods sold				167,124
Amortization, including amounts charged to interest expense				116,931
Provision for doubtful accounts				11,310
Provision (benefit) for deferred income taxes				(219,535)
Warrants income				(120,275)
Share-based compensation				56,561
LIFO (credit) expense				274,305
Pension settlement				47,607
Other				(6,446)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:
Accounts receivable				(705,462)
Merchandise inventories				(949,887)
Prepaid expenses and other assets				35,270
Accounts payable				1,776,565
Accrued expenses, income taxes, and other liabilities				53,575
NET CASH PROVIDED BY OPERATING ACTIVITIES				1,821,958
INVESTING ACTIVITIES
Capital expenditures				(310,178)
Cost of acquired companies, net of cash acquired				(2,731,356)
Cost of equity investments				(19,034)
Proceeds from sales of investment securities available-for-sale				101,829
Purchases of investment securities available-for-sale				(41,136)
Other				(21,186)
NET CASH USED IN INVESTING ACTIVITIES				(3,021,061)
FINANCING ACTIVITIES
Term loan borrowings				1,000,000
Senior notes and term loans repayments				(600,000)
Borrowings under revolving and securitization credit facilities				8,788,432
Repayments under revolving and securitization credit facilities				(8,273,610)
Purchases of common stock				(1,023,149)
Exercises of warrants				1,168,891
Exercises of stock options, including excess tax benefits of $21,853 in fiscal 2016				73,356
Cash dividends on common stock				(215,070)
Tax withholdings related to restricted share vesting				(18,935)
Other				(3,052)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES				896,863
DECREASE IN CASH AND CASH EQUIVALENTS				(302,240)
Cash and cash equivalents at beginning of period				2,167,442
CASH AND CASH EQUIVALENTS AT END OF PERIOD		1,865,202		1,865,202
Cash flow, parenthetical information:
Excess tax benefits from exercises of stock options				21,853
Adjustments \| Error Correction, Lease Accounting
OPERATING ACTIVITIES
Net income		(648)		(2,071)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, including amounts charged to cost of goods sold				4,629
Amortization, including amounts charged to interest expense				30
Provision for doubtful accounts				0
Provision (benefit) for deferred income taxes				(1,204)
Warrants income				0
Share-based compensation				0
LIFO (credit) expense				0
Pension settlement				0
Other				0
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:
Accounts receivable				0
Merchandise inventories				0
Prepaid expenses and other assets				0
Accounts payable				0
Accrued expenses, income taxes, and other liabilities				634
NET CASH PROVIDED BY OPERATING ACTIVITIES				2,018
INVESTING ACTIVITIES
Capital expenditures				0
Cost of acquired companies, net of cash acquired				0
Cost of equity investments				0
Proceeds from sales of investment securities available-for-sale				0
Purchases of investment securities available-for-sale				0
Other				0
NET CASH USED IN INVESTING ACTIVITIES				0
FINANCING ACTIVITIES
Term loan borrowings				0
Senior notes and term loans repayments				0
Borrowings under revolving and securitization credit facilities				0
Repayments under revolving and securitization credit facilities				0
Purchases of common stock				0
Exercises of warrants				0
Exercises of stock options, including excess tax benefits of $21,853 in fiscal 2016				0
Cash dividends on common stock				0
Tax withholdings related to restricted share vesting				0
Other				(2,018)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES				(2,018)
DECREASE IN CASH AND CASH EQUIVALENTS				0
Cash and cash equivalents at beginning of period				0
CASH AND CASH EQUIVALENTS AT END OF PERIOD		$ 0		0
Cash flow, parenthetical information:
Excess tax benefits from exercises of stock options				$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 100.8		$ 100.8
Unrecognized tax benefits, net of federal benefit	72		72
Unrecognized tax benefits - interest and penalties	15.1		15.1
Unrecognized tax benefits - increase (decrease)			12.6
Significant change in unrecognized tax benefits is reasonably possible	$ 4.8		$ 4.8
Effective tax rate	62.20%	29.60%	34.90%	(6.90%)

Goodwill and Other Intangible34

Goodwill and Other Intangible Assets - Schedule of Change in the Carrying Value of Goodwill by Reportable Segment (Details) $ in Thousands	9 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Roll Forward]
Goodwill	$ 5,991,497
Goodwill recognized in connection with acquisitions	54,136
Goodwill disposed in connection with divestiture	(3,564)
Foreign currency translation	483
Goodwill	6,042,552
Operating segments \| Pharmaceutical Distribution Services
Goodwill [Roll Forward]
Goodwill	4,264,485
Goodwill recognized in connection with acquisitions	0
Goodwill disposed in connection with divestiture	0
Foreign currency translation	0
Goodwill	4,264,485
Operating segments \| Other
Goodwill [Roll Forward]
Goodwill	1,727,012
Goodwill recognized in connection with acquisitions	54,136
Goodwill disposed in connection with divestiture	(3,564)
Foreign currency translation	483
Goodwill	$ 1,778,067

Goodwill and Other Intangible35

Goodwill and Other Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, Accumulated Amortization	$ (466,021)	$ (346,780)
Intangible Assets
Gross Carrying Amount	3,337,447	3,314,629
Net Carrying Amount	2,871,426	2,967,849
Trade names
Indefinite-lived intangibles
Indefinite-lived intangibles	685,016	684,991
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, Gross Carrying Amount	2,326,034	2,322,404
Finite-lived intangibles, Accumulated Amortization	(374,591)	(273,638)
Finite-lived intangibles, Net Carrying Amount	1,951,443	2,048,766
Trade names and other
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, Gross Carrying Amount	326,397	307,234
Finite-lived intangibles, Accumulated Amortization	(91,430)	(73,142)
Finite-lived intangibles, Net Carrying Amount	$ 234,967	$ 234,092

Goodwill and Other Intangible36

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 40	$ 40.3	$ 120.2	$ 112.2
Amortization expense, fiscal year maturity
2,017					$ 161.1
2,018					161.3
2,019					156.6
2,020					152
2,021					150.7
Thereafter					$ 1,525.3

Debt - Schedule of Debt Instrum

Debt - Schedule of Debt Instruments (Details) - USD ($)	Jun. 30, 2017	May 31, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Long-term debt	$ 3,433,193,000		$ 4,186,703,000
Less current portion	4,119,000		610,210,000
Total, net of current portion	3,429,074,000		3,576,493,000
Revolving credit note
Debt Instrument [Line Items]
Long-term debt	0		0
Receivables securitization facility due 2019
Debt Instrument [Line Items]
Long-term debt	500,000,000		500,000,000
Term loans due in 2020
Debt Instrument [Line Items]
Long-term debt	547,659,000		697,055,000
Multi-currency revolving credit facility due 2021
Debt Instrument [Line Items]
Long-term debt	0		0
Overdraft facility due 2021
Debt Instrument [Line Items]
Long-term debt	4,119,000		11,275,000
$600,000, 1.15% senior notes due 2017
Debt Instrument [Line Items]
Principal amount	$ 600,000,000
Interest rate	1.15%	1.15%
Long-term debt	$ 0		598,935,000
$400,000, 4.875% senior notes due 2019
Debt Instrument [Line Items]
Principal amount	$ 400,000,000
Interest rate	4.875%
Long-term debt	$ 398,217,000		397,669,000
$500,000, 3.50% senior notes due 2021
Debt Instrument [Line Items]
Principal amount	$ 500,000,000
Interest rate	3.50%
Long-term debt	$ 497,748,000		497,361,000
$500,000, 3.40% senior notes due 2024
Debt Instrument [Line Items]
Principal amount	$ 500,000,000
Interest rate	3.40%
Long-term debt	$ 496,643,000		496,276,000
$500,000, 3.25% senior notes due 2025
Debt Instrument [Line Items]
Principal amount	$ 500,000,000
Interest rate	3.25%
Long-term debt	$ 494,779,000		494,266,000
$500,000, 4.25% senior notes due 2045
Debt Instrument [Line Items]
Principal amount	$ 500,000,000
Interest rate	4.25%
Long-term debt	$ 494,028,000		$ 493,866,000

Debt - Additional information (

Debt - Additional information (Details)	1 Months Ended				9 Months Ended		29 Months Ended
Debt - Additional information (Details)	May 31, 2017USD ($)	Mar. 31, 2016USD ($)	Nov. 30, 2015USD ($)	Feb. 28, 2015USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2017GBP (£)	Jun. 30, 2017USD ($)
Debt Instrument [Line Items]
Repayments of long-term debt					$ 750,000,000	$ 600,000,000
$600,000, 1.15% senior notes due 2017
Debt Instrument [Line Items]
Repayments of long-term debt	$ 600,000,000
Interest rate	1.15%							1.15%	1.15%
Multi-currency revolving credit facility due 2021
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 1,400,000,000
Facility fee					0.09%
Multi-currency revolving credit facility due 2021 \| Minimum
Debt Instrument [Line Items]
Facility fee					0.05%
Multi-currency revolving credit facility due 2021 \| Maximum
Debt Instrument [Line Items]
Facility fee					0.15%
Multi-currency revolving credit facility due 2021 \| CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee
Debt Instrument [Line Items]
Variable rate spread					0.91%
Multi-currency revolving credit facility due 2021 \| CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee \| Minimum
Debt Instrument [Line Items]
Variable rate spread					0.70%
Multi-currency revolving credit facility due 2021 \| CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee \| Maximum
Debt Instrument [Line Items]
Variable rate spread					1.10%
Multi-currency revolving credit facility due 2021 \| Alternate base rate and Canadian prime rate \| Minimum
Debt Instrument [Line Items]
Variable rate spread					0.00%
Multi-currency revolving credit facility due 2021 \| Alternate base rate and Canadian prime rate \| Maximum
Debt Instrument [Line Items]
Variable rate spread					0.10%
Commercial paper
Debt Instrument [Line Items]
Maximum borrowing capacity									1,400,000,000
Debt instrument, term					365 days
Amount outstanding									0
Receivables securitization facility due 2019
Debt Instrument [Line Items]
Maximum borrowing capacity									1,450,000,000
Potential increase in receivables securitization facility					$ 250,000,000
Revolving credit note
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 75,000,000
Overdraft facility due 2021
Debt Instrument [Line Items]
Maximum borrowing capacity \| £								£ 30,000,000
February 2015 Term Loan
Debt Instrument [Line Items]
Repayments of long-term debt							$ 775,000,000
Maximum borrowing capacity				$ 1,000,000,000
February 2015 Term Loan \| LIBOR
Debt Instrument [Line Items]
Variable rate spread					1.00%
February 2015 Term Loan \| LIBOR \| Minimum
Debt Instrument [Line Items]
Variable rate spread				0.75%
February 2015 Term Loan \| LIBOR \| Maximum
Debt Instrument [Line Items]
Variable rate spread				1.25%
February 2015 Term Loan \| Base rate \| Minimum
Debt Instrument [Line Items]
Variable rate spread				0.00%
February 2015 Term Loan \| Base rate \| Maximum
Debt Instrument [Line Items]
Variable rate spread				0.25%
November 2015 Term Loan
Debt Instrument [Line Items]
Repayments of long-term debt		$ 25,000,000			$ 650,000,000
Maximum borrowing capacity			$ 1,000,000,000
November 2015 Term Loan \| LIBOR
Debt Instrument [Line Items]
Variable rate spread					1.00%
November 2015 Term Loan \| LIBOR \| Minimum
Debt Instrument [Line Items]
Variable rate spread			0.75%
November 2015 Term Loan \| LIBOR \| Maximum
Debt Instrument [Line Items]
Variable rate spread			1.25%
November 2015 Term Loan \| Base rate \| Minimum
Debt Instrument [Line Items]
Variable rate spread			0.00%
November 2015 Term Loan \| Base rate \| Maximum
Debt Instrument [Line Items]
Variable rate spread			0.25%

Stockholders' Equity and Earn39

Stockholders' Equity and Earnings per Share - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 30, 2016	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	May 31, 2016
Equity, Class of Treasury Stock [Line Items]
Percentage increase of cash dividend	7.00%
Cash dividends declared per share of common stock (usd per share)		$ 0.365	$ 0.365	$ 0.34	$ 0.34	$ 1.095	$ 1.02
Authorized amount under share repurchase program								$ 750,000,000
Antidilutive securities excluded from earnings per share computation (shares)		3.7			4.1	4.3	2.6
May 2016 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Repurchase of common stock (shares)			2.1
Settlement of accelerated share repurchase transaction (shares)			0.5
Repurchase of common stock			$ 118,800,000
November 2016 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Authorized amount under share repurchase program	$ 1,000,000,000
Repurchase of common stock (shares)						1.4
Repurchase of common stock						$ 111,100,000
Remaining availability under share repurchase program		$ 888,900,000				$ 888,900,000

Stockholders' Equity and Earn40

Stockholders' Equity and Earnings per Share - Weighted Average Number of Common Shares Outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Equity [Abstract]
Weighted average common shares outstanding - basic (shares)	218,676	215,688	218,336	209,898
Dilutive effect of stock options, restricted stock, and restricted stock units (shares)	3,197	3,042	3,362	3,440
Dilutive effect of Warrants (shares)	0	6,072	0	12,308
Weighted average common shares outstanding - diluted (shares)	221,873	224,802	221,698	225,646

Related Party Transactions (Det

Related Party Transactions (Details) - Walgreens Boots Alliance, Inc. - Investor - USD ($) $ in Billions	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Related Party Transaction [Line Items]
Revenue from related party	$ 11.2	$ 10.8	$ 33.4	$ 32.5
Receivable from related party	$ 5		$ 5		$ 4
AmerisourceBergen
Related Party Transaction [Line Items]
Ownership percentage (more than)	10.00%		10.00%

Employee Severance, Litigatio42

Employee Severance, Litigation, and Other (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Litigation settlements	$ 273,400	$ 0	$ 289,400	$ 0
Employee severance and other costs	9,584	34,554	21,767	40,247
Deal-related transaction costs	1,533	531	6,350	18,323
Transfer of surplus assets from a settled salaried defined benefit pension plan to a defined contribution 401(k) plan	0	17,149	0	17,149
Customer contract dispute settlements	0	0	0	13,000
Total employee severance, litigation, and other	$ 284,517	$ 52,234	$ 317,517	$ 88,719

Legal Matters and Contingenci43

Legal Matters and Contingencies (Details) $ in Thousands	Aug. 01, 2017USD ($)	Apr. 01, 2016USD ($)claim	Sep. 10, 2014USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)amendment	Jun. 30, 2016USD ($)
Loss Contingencies [Line Items]
Litigation settlements				$ 273,400	$ 0	$ 289,400	$ 0
USAO-EDNY Matter
Loss Contingencies [Line Items]
Litigation settlements				260,000		260,000
USAO-SDNY Matter
Loss Contingencies [Line Items]
Litigation settlements				13,400		13,400
West Virginia AG
Loss Contingencies [Line Items]
Litigation settlements						16,000
PMC Litigation \| Unpaid Invoices
Loss Contingencies [Line Items]
Gain contingency, damages sought (nearly)				$ 50,000		50,000
Gain contingency, number of counterclaims settled \| claim		1
Damages awarded to the company		$ 48,600
PMC Litigation \| Unpaid Invoices \| Subsequent Event
Loss Contingencies [Line Items]
Damages awarded to the company	$ 3,100
PMC Litigation \| Unpaid Rebates
Loss Contingencies [Line Items]
Loss contingency, damages sought (in excess of)			$ 8,000			$ 33,000
Loss contingency, number of amendments \| amendment						3
PMC Litigation \| Additional Breaches and Damages
Loss Contingencies [Line Items]
Loss contingency, damages sought (in excess of)						$ 100,000

Litigation Settlements (Details

Litigation Settlements (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Litigation Settlements (Details) - USD ($) $ in Millions	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Litigation Settlement [Abstract]
Gain from antitrust litigation settlements	$ 0	$ 121	$ 1.4	$ 133.8

Fair Value of Financial Instr45

Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Fixed-income securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amortized cost of investments	$ 100,400,000	$ 39,100,000
Estimate of Fair Value Measurement \| Level 2 inputs
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	3,521,200,000	3,750,900,000
Estimate of Fair Value Measurement \| Level 2 inputs \| Fixed-income securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale securities	100,400,000	39,100,000
Reported Value Measurement
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	3,429,100,000	3,576,500,000
Money market \| Estimate of Fair Value Measurement \| Level 1 inputs
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	0	650,000,000
Cash and cash equivalents \| Estimate of Fair Value Measurement \| Level 2 inputs \| Fixed-income securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale securities	$ 95,700,000	$ 13,000,000

Business Segment Information -

Business Segment Information - Segment Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 38,707,144	$ 36,881,680	$ 114,023,811	$ 109,289,083
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	(69,519)	(68,413)	(207,565)	(199,042)
Pharmaceutical Distribution Services \| Operating segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	37,032,709	35,373,725	109,127,631	104,734,137
Other \| Operating segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 1,743,954	$ 1,576,368	$ 5,103,745	$ 4,753,988

Business Segment Information 47

Business Segment Information - Segment Operating Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Total segment operating income	$ 170,376	$ 528,627	$ 1,195,344	$ 1,300,973
Operating segments
Segment Reporting Information [Line Items]
Total segment operating income	471,116	495,242	1,545,781	1,566,182
Intersegment eliminations
Segment Reporting Information [Line Items]
Total segment operating income	(198)	0	(212)	0
Pharmaceutical Distribution Services \| Operating segments
Segment Reporting Information [Line Items]
Total segment operating income	376,632	412,731	1,232,899	1,294,150
Other \| Operating segments
Segment Reporting Information [Line Items]
Total segment operating income	$ 94,682	$ 82,511	$ 313,094	$ 272,032

Business Segment Information 48

Business Segment Information - Reconciliation of Segment Operating Income to Income (Loss) from Operations before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Gain from antitrust litigation settlements	$ 0	$ 121,000	$ 1,400	$ 133,800
LIFO credit (expense)			82,919	(274,305)
Warrants income	0	83,704	0	120,275
Employee severance, litigation, and other	(284,517)	(52,234)	(317,517)	(88,719)
Pension settlement	0	0	0	(47,607)
Operating income	170,376	528,627	1,195,344	1,300,973
Other loss (income)	1,398	(2,158)	(3,958)	(3,224)
Interest expense, net	35,603	35,153	109,874	104,860
Income before income taxes	133,375	495,632	1,089,428	1,199,337
Operating segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating income	471,116	495,242	1,545,781	1,566,182
Segment reconciling items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Gain from antitrust litigation settlements	0	120,960	1,395	133,758
LIFO credit (expense)	24,723	(80,364)	82,919	(274,305)
Acquisition-related intangibles amortization	(40,946)	(38,681)	(117,234)	(108,611)
Warrants income	0	83,704	0	120,275
Employee severance, litigation, and other	(284,517)	(52,234)	(317,517)	(88,719)
Pension settlement	$ 0	$ 0	$ 0	$ (47,607)